Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development


Absci has announced that leading researchers at the California Institute of Technology (Caltech) in conjunction with Absci, a leader in AI drug creation, received a grant from the Bill & Melinda Gates Foundation. The grant supports the joint effort of Caltech and Absci to discover affordable HIV therapeutic vaccinations.

The collaboration between Caltech and Absci, led by Dr. Pamela Bjorkman, brings together cutting-edge research capabilities and advanced technological expertise in structural biology and immunology, protein design, synthetic biology, and generative AI. By leveraging their combined strengths, the teams will work towards the development of a novel HIV therapy that first exposes and then binds to a highly conserved epitope binding site on HIV-1 to potentially both treat and protect against infection from all strains of HIV-1.